Greg Verdine’s LifeMine eyes the clinic next year with T-cell immunosuppressive and antifungal: #JPM24
11 Jan 2024
Immunotherapy
SAN FRANCISCO — LifeMine Therapeutics, a biotech informed by the long history of fungi, expects to enter the clinic early next year with a T-cell immunosuppressive and with an antifungal about six months later, CEO Greg Verdine told Endpoints News.
“I’m saying it for the first time that these are the two areas right now that we’re focusing in,” Verdine said in an interview on the sidelines of the annual JP Morgan Healthcare Conference in the Bay Area. The biotech is also working on oncology programs and elsewhere, he noted.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.